CIP2A Products

Description

Inhibition of protein phosphatase 2A (PP2A) activity has been identified as a prerequisite for the transformation of human cells. The protein, designated Cancerous Inhibitor of PP2A (CIP2A), interacts directly with the oncogenic transcription factor c-Myc, inhibits PP2A activity toward c-Myc serine 62 (S62), and thereby prevents c-Myc proteolytic degradation. In addition to its function in c-Myc stabilization, CIP2A promotes anchorage-independent cell growth and in vivo tumor formation. The oncogenic activity of CIP2A is demonstrated by transformation of human cells by overexpression of CIP2A. Importantly, CIP2A is overexpressed in two common human malignancies, head and neck squamous cell carcinoma (HNSCC) and colon cancer.

Bioinformatics

Entrez	57650 Human
Uniprot	NM_020890 Human Q8TCG1 Human
Product By Gene ID	57650
Alternate Names	Cancerous inhibitor of PP2A CIP2A FLJ12850 KIAA1524 MGC163436 p90 autoantigen p90 protein CIP2A

Research Areas for CIP2A

Find related products by research area and learn more about each of the different research areas below.

Cancer
Tumor Suppressors

Related CIP2A Blog Posts

Check out the latest blog posts on CIP2A.

CIP2A: The Cancerous Inhibitor of Protein Phosphatase 2A The autoantigen p90 is a recently discovered protein that binds to and inhibits Protein Phosphatase 2A (PP2A) activity, thereby playing a critical role in cancer progression. Thus, p90 was renamed the "cancerous inhibitory protein of PP2A" or CIP2A....    Read more.

CIP2A - A lean, mean, oncoprotein machine The CIP2A protein was originally identified as p90, a cytoplasmic auto-antigen from the serum of a cancer patient. It was later found to inhibit protein phosphatase 2A (PP2A) activity as well as interact with c-myc. CIP2A's inhibitory activity blocks ...    Read more.

Read more CIP2A related blogs.